News
GCVRZ
0.8711
0.00%
0.00
Sanofi appoints Belén Garijo CEO, effective May 1
PUBT · 1d ago
Sanofi shareholders approve EUR 4.12 dividend per share at annual meeting
PUBT · 1d ago
Regeneron beats quarterly results estimates on strong Dupixent demand
Reuters · 1d ago
Regeneron Q1 FY26 GAAP EPS drops 7% to $6.75; revenue climbs 19% to $3.6 billion
PUBT · 1d ago
Sanofi prices €2.3 billion bond issue in three tranches
PUBT · 1d ago
Immunic names Michael Panzara chief medical officer, replacing Andreas Muehler
PUBT · 2d ago
Sanofi says phase 4 study shows Nuvaxovid better tolerated than Moderna mNEXSPIKE
PUBT · 3d ago
Sanofi prices €2.3 billion bond issue in three tranches
PUBT · 5d ago
Sanofi MS drug Cenrifki wins CHMP backing for EU approval in non-relapsing SPMS
PUBT · 6d ago
PRESS RELEASE: SANOFI’S CENRIFKI (TOLEBRUTINIB) RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS WITHOUT RELAPSES
Reuters · 6d ago
Meiji Seika Pharma starts Japan Phase I/II trial of Rezurock in pediatric cGVHD
PUBT · 6d ago
Sanofi Q1 business EPS rises 14% to €1.88; net sales climb 13.6% to €10.5 billion
PUBT · 04/23 05:31
BRIEF-Sanofi Q1 Net Income EUR 1,614 Million
Reuters · 04/23 05:30
FDA approves Sanofi, Regeneron Dupixent for children 2-11 with chronic spontaneous urticaria
PUBT · 04/22 21:30
PRESS RELEASE: SANOFI AND REGENERON’S DUPIXENT APPROVED IN THE US AS THE FIRST BIOLOGIC MEDICINE FOR YOUNG CHILDREN WITH UNCONTROLLED CHRONIC SPONTANEOUS URTICARIA
Reuters · 04/22 21:30
DUPIXENT® (DUPILUMAB) APPROVED IN THE U.S. AS THE FIRST BIOLOGIC MEDICINE FOR YOUNG CHILDREN WITH UNCONTROLLED CHRONIC SPONTANEOUS URTICARIA (CSU)
Reuters · 04/22 21:30
BRIEF-Sanofi's Tzield Approved In US To Delay Onset Of Stage 3 Type 1 Diabetes In Young Children
Reuters · 04/22 05:28
FDA approves Sanofi Tzield for stage 2 type 1 diabetes in children age 1+
PUBT · 04/22 05:06
PRESS RELEASE: SANOFI'S TZIELD APPROVED IN THE US TO DELAY THE ONSET OF STAGE 3 TYPE 1 DIABETES IN YOUNG CHILDREN
Reuters · 04/22 05:05
FDA extends review of Sanofi Sarclisa subcutaneous to July 23 target date
PUBT · 04/22 05:00
More
Webull provides a variety of real-time GCVRZ stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About GCVRZ
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.